BioMS Medical's Pivotal International Multiple Sclerosis Trial Receives Positive Review From Data Safety Monitoring Board

Main Category: Multiple Sclerosis
Also Included In: Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 15 Dec 2007 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that following the meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue MAESTRO-01, its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis.

This was the eighth of several regularly scheduled reviews by the DSMB, including the planned in-depth interim safety analysis, held in April 2007, on the first 100 patients enrolled in the study who had completed twelve months of treatment. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

BioMS Medical Corp.
http://www.biomsmedical.com